A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

NCT06992687 | Enrolling By Invitation Phase 1 FDA Drug

• 1 other identifier: HB0052-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors

Conditions

Solid Tumors

Keywords

HB0052

Outcome Measures

Primary Outcomes (2)

• Safety and tolerability

  Number of participants with a Dose Limiting Toxicity (DLT) \[ Time Frame: During the first 21 days \]DLTs will be assessed during the first 21 days of treatment for dose-escalation phase and are defined as toxicities that meet pre defined severity criteria, and assessed as having a suspected or definite relationship to study drug

  Up to 12 Months

• MTD

  MTD or OBD and/or RP2D.

  Up to 24 Months

Secondary Outcomes (3)

• AUC

  Up to 24 Months

• Cmax

  Up to 24 Months

• Tmax

  Up to 24 Months

Other Outcomes (1)

• ORR assessment in dose-escalation phase

  Up to 24 Months

Study Arms (1)

HB0052

EXPERIMENTAL

IV every 3 weeks (q3w)

Drug: HB0052 Injection

Interventions

HB0052 Injection DRUG

An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload

HB0052

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, aged ≥ 18 years
• The subject is able to understand and willing to sign the ICF and is willing and able to comply with all study procedures.
• Patients with known UGT1A1 genotype determination results or is willing to accept UGT1A1 genotype determination test.
• For subjects in phase 2 studies, previous tumor biopsy specimens or fresh tumor biopsy specimens is required.
• Phase I: Patients with histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors (or clinically diagnosed hepatocellular carcinoma) that failed (progressed on or are intolerant of) all standard therapies known to provide clinical benefit \[These solid tumors include but not limited to: pancreatic, colorectal, ovarian, breast, lung, head and neck, prostate, renal cancer and sarcoma, etc.\].
• Phase II: Patients who have had at least one prior systemic therapy and has progressed, and might benefit from the study drug in the Investigator's judgment, and have the following histological types (The types of tumors and the number of treatment lines may be adjusted based on phase I results and /or SRC discussions):
• a.Pancreatic cancer cohort: i.Histologically or cytologically confirmed unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma; b.Endometrial carcinoma cohort: i.advanced/unresectable, recurrent, or metastatic endometrial carcinoma, or recurrent, metastatic histologically uterine serous papillary carcinoma (USPC) with measurable disease.
• c.Gastric and GEJ adenocarcinoma cohort: i.Histologically or cytologically confirmed locally advanced unresectable or metastatic gastric and GEJ adenocarcinoma ii.HER2 low expression and negative for claudin 18.2 d.RCC cohort: i.Pathologically (histologically or cytologically) proven of locally advanced unresectable or metastatic renal cell carcinoma.
• e.HCC cohort: i.inoperable locally advanced, recurrent, or metastatic HCC ii.Patients with Child-Pugh grade A liver function
• f.Other histologically confirmed unresectable, locally advanced or metastatic advanced solid tumor cohort(s): Tumor specific type that demonstrated partial response to HB0052 in the dose escalation phase.
• At least one measurable lesion as per RECIST v. 1.1 defined as non-nodal lesions having at least one dimension with a minimum size of 10 mm in the longest diameter by CT or MRI scan or ≥15 mm in short axis for nodal lesions. Radiographic disease assessment at baseline can be performed up to 28 days prior to the first dose.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
• Life expectancy ≥12 weeks.
• Patients with active hepatitis B virus (HBV) without active disease (HBV DNA titer \<1000 cps/mL or 200 IU/mL), or who are cured of hepatitis C virus (HCV) with a negative HCV RNA test may be enrolled at the investigator's discretion.
• Patients with known human immunodeficiency virus (HIV) infection and a cluster of differentiation 4 (CD4) count that is tested or documented to be ≥350 cells/mm3 within 12 months before study screening.

You may not qualify if:

• Concurrent malignancy \< 5 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or \< T1 urothelial carcinoma. Patients with prostate cancer that is under active surveillance are eligible.
• Patients with Gilbert's disease
• Patients with a history of COPD or other severe respiratory disease in the 6 months before screening
• Patients with active ≥ grade 2 anorexia, nausea or vomiting.
• Patients with a history of intestinal obstruction or perforation in the 6 months before screening
• Patients with grade 3 or higher toxicity due to irinotecan use
• Patients with reduced UGT1A1 activity or who are predisposed to or have a history of chronic diarrhea.
• Have clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain or meningeal metastases may participate and be eligible for treatment provided they are stable and asymptomatic. Patients with asymptomatic brain or meningeal metastasis or patients who are symptomatically stable after treatment and are on ≤ 10 mg/d prednisone or equivalent are eligible.
• Cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction (MI), unstable angina, or New York Heart Association (NYHA) class III or IV heart failure occurred within 6 months before study admission；Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \> 450 millisecond (ms) in males and \> 470 ms in female; malignant arrhythmia \< 3 months of study entry (judged by the Investigator). Has a history of cardiomyopathy or myocarditis. Patients with rate-controlled arrhythmias may be eligible for study entry at discretion of the Investigator.
• Active autoimmune disease or history of autoimmune disease requiring systemic therapy \< 2 years prior to screening. The following exceptions can be included: hypothyroidism, vitiligo, Graves' disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible.
• Patients who have previously received allogeneic stem cell or solid organ transplantation.
• History of severe allergic reactions, Grade 3-4 allergic reactions to treatment with another monoclonal antibody or known to be allergic to protein drugs or recombinant proteins or excipients in HB0052 drug formulation.
• History of Gr3-4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies, (except for Gr3 endocrinopathy that is managed with hormone replacement therapy).
• Continuous systemic corticosteroids administration in a dose equivalent to 10 mg/day or more of prednisone or prednisone-equivalent or other immunosuppressants for 5 days or more within 2 weeks before screening. The following exceptions are allowed: the use of corticosteroids in a short course (within one week) to administration topical, intraocular, intraarticular, intranasal, or inhaled are allowed.
• Have received or will receive a live vaccine within 4 weeks prior to the first dose.

Sponsors & Collaborators

• Shanghai Huaota Biopharmaceutical Co., Ltd.: lead
• Peking University Cancer Hospital & Institute: collaborator
• Zhejiang Cancer Hospital: collaborator
• Shandong Cancer Hospital and Institute: collaborator
• Hunan Cancer Hospital: collaborator
• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: collaborator
• The Second Affiliated Hospital of Harbin Medical University: collaborator
• Huazhong University of Science and Technology: collaborator

Study Sites (1)

Peking University Cancer Hospital

Beijing, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2025
• First Posted: May 28, 2025
• Study Start: September 1, 2024
• Primary Completion: September 30, 2025
• Study Completion: November 30, 2025
• Last Updated: May 28, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)